title: Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery.
abstract: Twenty patients with Zollinger-Ellison syndrome who were undergoing surgery were studied prospectively to assess the efficacy and safety of IV omeprazole. During the preoperative period, in 19 of 20 patients, omeprazole 60 mg administered as an IV bolus every 12 hours inhibited acid output to less than 5 mEq/h measured in the last hour before the next dose of drug. In one patient, acid output was 25 mEq/h 12 hours after omeprazole, 60 mg, and increasing the dose to 100 mg every 12 hours reduced acid output to less than 5 mEq/h. During the operative and postoperative periods, IV omeprazole controlled gastric acid hypersecretion in all patients for up to 15 days. During this time, all patients received the dose determined preoperatively. No patient developed any clinical, hematological, or biochemical toxicity that could be attributed to omeprazole therapy during the preoperative or postoperative period. The present study demonstrates that omeprazole administered by IV bolus is safe and effective for controlling gastric acid hypersecretion. In contrast to IV histamine H2-receptor antagonists, IV omeprazole has the advantages of not requiring continuous infusion or postoperative dose adjustments. Intravenous omeprazole will become the drug of choice in patients with Zollinger-Ellison syndrome undergoing surgery.
authors.affiliation: Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: R
authors.initials: R
authors.lastname: Vinayek
authors.forename: H
authors.initials: H
authors.lastname: Frucht
authors.forename: J F
authors.initials: JF
authors.lastname: London
authors.forename: L S
authors.initials: LS
authors.lastname: Miller
authors.forename: H A
authors.initials: HA
authors.lastname: Stark
authors.forename: J A
authors.initials: JA
authors.lastname: Norton
authors.forename: C
authors.initials: C
authors.lastname: Cederberg
authors.forename: R T
authors.initials: RT
authors.lastname: Jensen
authors.forename: J D
authors.initials: JD
authors.lastname: Gardner
authors.forename: P N
authors.initials: PN
authors.lastname: Maton
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D011184:Postoperative Period; D011446:Prospective Studies; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy* / Q000601:surgery
chemical_list: D006635:Histamine H2 Antagonists; D009853:Omeprazole